Use of the COVID-19 treatment Paxlovid (nirmatrelvir/ritonavir) is picking up in the US after some initial challenges getting the antiviral to the right patients quickly, but there is still a lot of work to do on expanding access and educating physicians and patients about the treatment, Pfizer Inc. said during its first quarter sales and earnings call on 3 May.
The addition of Paxlovid and the COVID-19 vaccine Comirnaty, partnered with BioNTech SE, are providing a big boost to...







